DGAP-News: EBD Group: Twenty-fifth annual BIO-Europe(R) to bring 4,400 life science leaders to Hamburg November 11-13
DGAP-News: EBD Group
/ Key word(s): Conference
EBD Group: Twenty-fifth annual BIO-Europe(R) to bring 4,400 life science leaders to Hamburg November 11-13
14.10.2019 / 14:00
The issuer is solely responsible for the content of this announcement.
Twenty-fifth annual BIO-Europe(R) to bring 4,400 life science leaders to Hamburg November 11-13
Carlsbad, CA and Hamburg, Germany - October 14, 2019: This 25th anniversary BIO-Europe(R) international partnering conference, November 11-13 in Hamburg, Germany, will focus on top industry visions for the next 25 years while taking a look at the most formative turning points in the past two and a half decades. For a preview take a look at the e-book published ahead of the keynote, Back to the Future: Milestones from the last 25 years.
Top-notch experts will also highlight cutting-edge innovations in women's health, immuno-oncology, cardiology and digital medicine; important business development trends in China market investment, non-binding term sheets, and funding unmet needs; and European market access.
The program also features a Startup Slam pitching competition sponsored by Johnson & Johnson Innovation/JLABS, offering emerging entrepreneurs a chance to pitch their innovative technologies to a panel of leading investors, pharma dealmakers, and biotech key opinion leaders.
This year's conference takes place in Hamburg for the third time in its 25 years, supported by regional hosts Life Science Nord, the City of Hamburg, and the State of Schleswig-Holstein. The event is expected to bring together 4,400 executives from 2,300+ life sciences companies spanning an estimated 60+ countries to engage in one-to-one partnering.
Registration and event information are available online.
High-level executives from pharma, biotech, the investment sector and patient groups are confirmed to attend for three days of productive partnering meetings, with many also leading program panels and discussions detailed here.
Featured speakers:
Kate Bingham - Managing Partner, SV Life Sciences Advisers
Hubert Birner - Managing Partner, TVM Capital Life Science
Jasper Bos - Senior VP and Managing Director, M Ventures
Isabelle de Cremoux - CEO and Managing Partner, Seventure
Yann Ferrisse - Head of Business Development, Global Antibiotic R&D Partnership (GARDP)
Junjun Gao - Senior Associate Director, External Innovation, Boehringer Ingelheim
Martin Gouldstone - Global SVP, Syneos One, Capital Solutions, Syneos Health
Annalisa Jenkins - Chair of the Board of Directors, Cell Medica
Claudia Karnbach - Head, Global Business Development and Licensing, Specialty Medicine, Pharmaceuticals Division, Bayer
Werner Lanthaler - CEO, Evotec AG
Phil L'Huillier - Head, European Innovation Hub, MSD
Rana Lonnen - Head, Search and Evaluation, Strategic Venture Capital, Novartis
Angeli Moeller - Head IT Business Partnering Research, Bayer
Jane Osbourn - VP, Research and Development, AstraZeneca and Chair, UK BioIndustry Association (BIA)
Paul Stoffels - Vice Chair of the Executive Committee and CSO, Johnson & Johnson
Lesley Stolz - EVP and CBO, Annexon
Friedrich von Bohlen - CEO, Molecular Health GmbH
Hot topics:
Top of the pops: Greats of the past, leaders of the future
Immuno-oncology: Optimizing success in the crowded partnering market, and trends for 2020
Evolving priorities in women's health
Workable business models for AMR innovation
Digital therapeutic partnership landscape
The China market: Valuable opportunities, sophisticated business models, novel science
Emerging pharma first launch and partnering
Non-binding term sheet: Necessary evil or the key to success?
Market access Europe: How do smaller biotechs interact best with Europe's decision makers?
Dealmaking in the microbiome field: The coming of age
Gene therapy valuation and deal trends
Best path forward for successful product development
Watch video coverage from previous events, interviews with executives and thought leaders in the life science industry and premier content related to the biopharma industry on EBD Group's Partnering Insight.
# # #
Additional links and information:
Follow BIO-Europe on Twitter: @EBDGroup (hashtag: #BIOEurope).
About EBD Group
EBD Group's overriding mission is to help collaborations get started across the life sciences value chain. Our range of partnering conferences has grown to become the largest and most productive conference platform in the industry. Each one of our landmark events held in key life sciences markets around the world is powered by our state-of-the-art partnering software, partneringONE(R), that enables delegates to efficiently identify and engage with new opportunities via one-to-one meetings.
Today our events (BIO-Europe(R), BIO-Europe Spring(R), BioPharm America(TM), Biotech Showcase(TM), China Showcase, Digital Medicine & Medtech Showcase, ChinaBio(R) Partnering Forum, Rare Disease Innovation and Partnering Summit, Cell & Gene Meeting on the Med, and BioEquity Europe) annually attract more than 15,000 senior life sciences executives who engage in over 50,000 one-to-one partnering meetings. These vital one-to-one engagements are the wellspring of deals that drive innovation in our industry.
Tune into EBD Group's Partnering Insight for timely coverage of news that influences the business strategies of the life sciences industry. EBD Group is an Informa company. For more information please visit www.ebdgroup.com.
Media contact:
Kari Bennett, EBD Group: +1 760 930 0500; kbennett@ebdgroup.comEuropean media support:
Anne Hennecke, MC Services AG: +49 211 529 252 22; anne.hennecke@mc-services.eu
14.10.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
889229 14.10.2019